By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ImmuPharma plc 

50 Broadway
London    SW1H 0RG  United Kingdom
Phone: 44-20-7152-4080 Fax: 44-20-7152-4001



Company News
ImmuPharma plc (IMM.L) Release: Company Update On Lupuzor Pivotal Phase III Study Full Analysis Of Patient Recruitment 1/25/2017 9:21:04 AM
ImmuPharma plc (IMM.L) Release: Landmark Collaboration Agreement & Commencement Of Pivotal Phase 3 Lupuzor™ Study With Simbec-Orion Deal Provides Powerful Validation For Lupuzor™ 1/22/2015 10:12:32 AM
ImmuPharma plc (IMM.L) on 7/10/2012 8:40:45 AM
ImmuPharma plc (IMM.L)'s Lupuzorâ„¢ Granted Approval to Start Phase III and Fast Track Designation by the FDA 11/3/2011 8:43:34 AM
ImmuPharma plc (IMM.L) Regains Lupuzor Rights from Cephalon, Inc. (CEPH) Due to Teva Pharmaceutical Industries Limited (TEVA) Merger 10/21/2011 6:59:23 AM
ImmuPharma plc (IMM.L) - Preliminary Results for the Year Ended 31 December 2010 4/5/2011 8:47:34 AM
ImmuPharma plc (IMM.L) - Notification of Preliminary Results 3/30/2011 9:34:53 AM
ImmuPharma plc (IMM.L) - Update on Progress of Phase I/IIa Clinical Trial 2/22/2011 10:52:55 AM
ImmuPharma plc (IMM.L) Release: Preliminary Results Announcement For The Year Ended 31 December 2009 5/19/2010 2:53:07 PM
ING Takes 4% Stake In ImmuPharma plc (IMM.L) 1/13/2010 10:20:46 AM